-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WwewaJgBvVNXtw8SizjIYaAYvOy4DCvzKgUAIXjJtqi1s4fVK0Tn7FgiF7gLNv7p
 OACxfy2W54UrnbdGy73HCA==

<SEC-DOCUMENT>0000200406-05-000064.txt : 20050419
<SEC-HEADER>0000200406-05-000064.hdr.sgml : 20050419
<ACCEPTANCE-DATETIME>20050419150135
ACCESSION NUMBER:		0000200406-05-000064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20050419
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050419
DATE AS OF CHANGE:		20050419

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		05759076

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		7325242454
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eightkcover.txt
<TEXT>


               SECURITIES AND EXCHANGE COMMISSION
                     Washington, D.C. 20549


                            FORM 8K

                        Current Report
               Pursuant to Section 13 or 15(d) of
              The Securities Exchange Act of 1934



  Date of Report (Date of earliest event reported):
April 19, 2005


                        JOHNSON & JOHNSON

     (Exact name of registrant as specified in its
charter)


  New Jersey             1-3215           22-1024240

(State or other        Commission     (I.R.S. Employer
jurisdiction          File Number)   Identification No.)
of incorporation)



 One Johnson & Johnson Plaza, New Brunswick, New Jersey
08933

    (Address of principal executive offices)   (zip code)


Registrant's telephone number including area code:
(732) 524-0400

Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following
provisions:

[ ] Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Item 2.02 Results of Operations and Financial Condition

On April 19, 2005, Johnson & Johnson ("J&J") issued the
attached   press  release  announcing  its  sales   and
earnings for the first quarter ended April 3, 2005.


Item 9.01 Financial Statements and Exhibits

Exhibit No.         Description of Exhibit

99.15     Press Release dated April 19, 2005 for the
          period ended April 3, 2005.

99.2O     Unaudited Comparative Supplementary
          Sales Data and Condensed Consolidated
          Statement of Earnings for the first quarter.





                            SIGNATURE



Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto
duly authorized.



                                   JOHNSON & JOHNSON




Date: April 19, 2005      By: /s/ Stephen J. Cosgrove
                              Stephen J. Cosgrove
                              Chief Accounting Officer




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.15 OTH FIN ST
<SEQUENCE>2
<FILENAME>results.txt
<TEXT>
Exhibit 99.15
Johnson & Johnson Reports 2005 First Quarter EPS Rose 16.9%
on Sales Increase of 11.0%
New Brunswick, NJ (April 19, 2005) - Johnson & Johnson today
announced sales for the first quarter of 2005 of $12.8
billion, an increase of 11.0% over the prior year. The
increase was attributable to operational growth of 8.8% and
a favorable currency impact of 2.2%. Domestic sales were up
4.9%, while international sales increased 20.1%, reflecting
operational growth of 14.7% and a positive currency impact
of 5.4%.

Net earnings and diluted earnings per share for the first
quarter were $2.9 billion and $.97, increases of 17.4% and
16.9%, respectively, as compared with the same period in
2004.

"Our strategic principle of being broadly based continues to
serve us well," said William C. Weldon, Chairman and Chief
Executive Officer. "I'm pleased that the strong performance
of each of the franchises in our Medical Devices and
Diagnostics segment and the solid results in our Consumer
segment were able to add to the more modest increase from
our Pharmaceutical business during the quarter."

Worldwide Medical Devices and Diagnostics sales of $4.8
billion for the first quarter represented an increase over
the prior year of 16.0%, with operational growth of 13.4%
and a positive impact from currency of 2.6%. Domestic sales
increased 7.6%, while international sales increased 25.4%
(19.9% from operations and 5.5% from currency).

All franchises were contributors to the operational growth,
which included DePuy's orthopaedic joint reconstruction and
spinal products; LifeScan's blood glucose monitoring
products; Vistakon's disposable contact lenses; Ortho-
Clinical Diagnostics' professional diagnostic products;
Ethicon's wound care and women's health products; Ethicon
Endo-Surgery's minimally invasive products, and Cordis'
circulatory disease management products.

During the quarter, the Company announced that it had
entered into a definitive agreement to acquire CLOSURE
Medical Corporation, a global leader in biomaterial-based
medical devices.

Worldwide Pharmaceutical sales of $5.8 billion for the first
quarter represented an increase over the prior year of 7.0%,
with operational growth of 5.3% and a positive impact from
currency of 1.7%. Domestic sales increased 3.8%, while
international sales increased 13.8% (8.5% from operations
and 5.3% from currency).

Sales growth reflects the strong performance of REMICADEr
(infliximab), a treatment for rheumatoid arthritis, Crohn's
disease and ankylosing spondylitis; TOPAMAXr (topiramate),
an antiepileptic and a treatment for the prevention of
migraine headaches; RISPERDALr (risperidone) and RISPERDALr
CONSTAT (risperidone), an antipsychotic medication;
LEVAQUINr (levofloxacin), an anti-infective; CONCERTAr
(methylphenidate HCl), a treatment for attention deficit
hyperactivity disorder and ACIPHEXr/PARIETT (rabeprazole
sodium), a proton pump inhibitor for gastrointestinal
disorders. PROCRITr/EPREXr (Epoetin alfa), a product for the
treatment of anemia, was negatively impacted by competition
and both the hormonal contraceptive franchise and DURAGESICr
(fentanyl transdermal system), a transdermal patch for
chronic pain, were negatively impacted by generic
competition.

In April, the Company announced the completion of its
acquisition of TransForm Pharmaceuticals, Inc., which
specializes in the discovery of superior formulations and
novel crystalline forms of drug molecules. In addition, the
Company submitted a new drug application to the U.S. Food
and Drug Administration (FDA) for REMICADEr (infliximab) for
the treatment of ulcerative colitis.

Worldwide Consumer segment sales of $2.3 billion for the
first quarter represented an increase over the prior year of
11.4%, with operational growth of 8.9% and a positive impact
from currency of 2.5%. Domestic sales increased 3.1%, while
international sales increased 20.7% (15.4% from operations
and 5.3% from currency).

Strong growth in Consumer sales was achieved by McNeil
Consumer & Specialty Pharmaceuticals' over-the-counter adult
TYLENOLr (acetaminophen) products, McNeil Nutritional's
SPLENDAr (sucralose) sweetener and the skin care lines of
RoCr and AVEENOr.

Johnson & Johnson is the world's most comprehensive and
broadly based manufacturer of health care products, as well
as a provider of related services, for the consumer,
pharmaceutical, and medical devices and diagnostics markets.
The more than 200 Johnson & Johnson operating companies
employ approximately 111,000 men and women in 57 countries
and sell products throughout the world.

NOTE TO INVESTORS
Johnson & Johnson will conduct a conference call with
financial analysts to discuss this news release today at
8:30 a.m., Eastern Daylight Savings Time. A simultaneous
webcast of the call for interested investors and others may
be accessed by clicking on the webcast icon from the jnj.com
Homepage or by clicking on Calendar of Events in the
Investor Relations section of the Web site. A replay will be
available approximately two hours after the live webcast by
clicking on "Webcasts/Presentations" in the Investor
Relations section.

(This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of
1995. These statements are based on current expectations of
future events. If underlying assumptions prove inaccurate or
unknown risks or uncertainties materialize, actual results
could vary materially from the Company's expectations and
projections. Risks and uncertainties include general
industry conditions and competition; economic conditions,
such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by
competitors; challenges inherent in new product development,
including obtaining regulatory approvals; domestic and
foreign health care reforms and governmental laws and
regulations; and trends toward health care cost containment.
A further list and description of these risks, uncertainties
and other factors can be found in Exhibit 99(b) of the
Company's Annual Report on Form 10-K for the fiscal year
ended January 2, 2005. Copies of this Form 10-K are
available online at www.sec.gov or on request from the
Company. The Company assumes no obligation to update any
forward-looking statements as a result of new information or
future events or developments.)

For  more information on Johnson & Johnson, please visit the
Company's website at http://www.jnj.com.
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2O OTH FIN ST
<SEQUENCE>3
<FILENAME>financials.txt
<TEXT>
Exhibit 99.2O

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)
                                 FIRST QUARTER
                    2005   2004 Percent  Percent    Percent
                                 Change  Change     Change
                                  Total  Operations Currency
Sales to customers
by segment of
business
 Consumer
   U.S.               $1,114  1,081     3.1 %     3.1       -
   International       1,166    966    20.7      15.4     5.3
                       2,280  2,047    11.4       8.9     2.5
 Pharmaceutical
   U.S.                3,783  3,643     3.8       3.8       -
   International       1,972  1,733    13.8       8.5     5.3
                       5,755  5,376     7.0       5.3     1.7

Med Devices &
Diagnostics
   U.S.                2,361  2,194     7.6       7.6       -
   International       2,436  1,942    25.4      19.9     5.5
                       4,797  4,136    16.0      13.4     2.6

U.S.                   7,258  6,918     4.9       4.9       -

International          5,574  4,641    20.1      14.7     5.4

Worldwide            $12,832 11,559    11.0 %     8.8     2.2



Johnson & Johnson and Subsidiaries
Supplementary Sales Data

(Unaudited; Dollars in Millions)
                                 FIRST QUARTER
                    2005   2004 Percent  Percent    Percent
                                 Change  Change     Change
                                  Total  Operations Currency
Sales to customers by
geographic area

U.S.                    $7,258   6,918    4.9 %     4.9       -

Europe                   3,176   2,708   17.3      11.2     6.1
Western Hemisphere         725     597   21.4      15.4     6.0
excluding U.S.
Asia-Pacific, Africa     1,673   1,336   25.2      21.5     3.7
International            5,574   4,641   20.1      14.7     5.4

Worldwide              $12,832  11,559   11.0 %     8.8     2.2



Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except
Per Share Figures)
                FIRST QUARTER
                                 2005             2004    Percent
                               Percent          Percent   Increase
                       2005       to    2004       to    (Decrease)
                     Amount     Sales  Amount    Sales

Sales to customers    $12,832     100.0 $11,559       100.0    11.0
Cost of products sold   3,482      27.1   3,367        29.1     3.4
Selling, marketing and  4,043      31.5   3,640        31.5    11.1
administrative
expenses
Research expense        1,347      10.5   1,095         9.5    23.0
Interest (income)         (69)     (0.5)      6         0.1
expense, net
Other (income)            (33)     (0.3)    (53)       (0.5)  (37.7)
expense, net
Earnings before         4,062      31.7   3,504        30.3    15.9
provision for taxes on
income
Provision for taxes on  1,135       8.9   1,011         8.7    12.3
income
Net earnings           $2,927      22.8  $2,493        21.6    17.4

Net earnings per share  $0.97             $0.83                16.9
(Diluted)

Average shares        3,023.7           3,004.6
outstanding (Diluted)

Effective tax rate       27.9 %            28.8 %


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
